A Phase 2 study of BEBT-109 in NSCLC with EGFR exon 20 mutations

Recruiting Phase 2 NCT06514027

Study Description

A study evaluating the safety and effectiveness of BEBT-109, alone or combined with chemotherapy, as a treatment for non-small cell lung cancer with a specific gene mutation

Study Details

Registry ID:
NCT06514027
Conditions:
Non Small Cell Lung Cancer
Phase:
Phase 2
Target Enrollment:
30 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →